UGT1A1 Haplotypes Associated with Reduced Glucuronidation and Increased Serum Bilirubin in Irinotecan‐administered Japanese Patients with Cancer

A comprehensive haplotype analysis of UGT1A1 in the Japanese population was conducted, and the effects of these haplotypes were investigated with respect to UGT1A1‐related phenotypic parameters in patients with cancer who received irinotecan.

[1]  T. Morisaki,et al.  Determination of probability distribution of diplotype configuration (diplotype distribution) for each subject from genotypic data using the EM algorithm , 2002 .

[2]  A. Di Rienzo,et al.  Phenotype‐genotype correlation of in vitro SN‐38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism , 1999, Clinical pharmacology and therapeutics.

[3]  S. Wrighton,et al.  Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank. , 2000, Pharmacogenetics.

[4]  M. Ratain,et al.  Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. , 1998, The Journal of clinical investigation.

[5]  Yoshiro Saito,et al.  GLUCURONIDATION OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN ( SN-38 ) , AN ACTIVE METABOLITE OF IRINOTECAN ( CPT-11 ) , BY HUMAN UGT 1 A 1 VARIANTS , 2002 .

[6]  J. Supko,et al.  Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Ratain,et al.  Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. , 1994, Cancer research.

[8]  Teruhiko Yoshida,et al.  Three novel single nucleotide polymorphisms in UGT1A9. , 2003, Drug metabolism and pharmacokinetics.

[9]  M. Mori,et al.  Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. , 2002, Biochemical and biophysical research communications.

[10]  J Verweij,et al.  Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Yoshiro Saito,et al.  Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin , 2001, Xenobiotica; the fate of foreign compounds in biological systems.

[12]  G. Luo,et al.  Variations of the bilirubin uridine-diphosphoglucuronosyl transferase 1A1 gene in healthy Taiwanese. , 2000, Pharmacogenetics.

[13]  K. Hayasaka,et al.  Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate‐glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese , 1998, Biochemistry and molecular biology international.

[14]  A. Di Rienzo,et al.  Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. , 2002, Pharmacogenetics.

[15]  K. Mizuno,et al.  A new enzymatic approach for estimating total and direct bilirubin. , 1988, Clinical biochemistry.

[16]  Yoshiro Saito,et al.  Comprehensive UGT1A1 genotyping in a Japanese population by pyrosequencing. , 2003, Clinical chemistry.

[17]  D Lindhout,et al.  The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. , 1995, The New England journal of medicine.

[18]  C. Guillemette,et al.  Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). , 2002, Molecular pharmacology.

[19]  L. Wienkers,et al.  Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[20]  H. Saka,et al.  Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. , 2000, Cancer research.

[21]  Teruhiko Yoshida,et al.  Three novel single nucleotide polymorphisms in UGT1A10. , 2002, Drug metabolism and pharmacokinetics.

[22]  S. Culine,et al.  Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. , 1994, Cancer research.

[23]  S. Ozawa,et al.  An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. , 2002, Biomedical chromatography : BMC.

[24]  R Judson,et al.  The predictive power of haplotypes in clinical response. , 2000, Pharmacogenomics.

[25]  B. Burchell,et al.  Genetic variation in bilirubin UDP-glucuronosyltransferase gene promoter and Gilbert's syndrome , 1996, The Lancet.

[26]  R. Schilsky,et al.  UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity , 2002, The Pharmacogenomics Journal.

[27]  J. Verweij,et al.  Modulation of irinotecan-induced diarrhea by cotreatment with neomycin in cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  E. Beutler,et al.  Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Verweij,et al.  Irinotecan (CPT-11) metabolism and disposition in cancer patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Yoshiro Saito,et al.  Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38), an active metabolite of irinotecan (CPT-11), by human UGT1A1 variants, G71R, P229Q, and Y486D. , 2003, Drug metabolism and disposition: the biological fate of chemicals.